Inhibikase Therapeutics, Inc.
USD2.23
+0.12 (+5.69%)
CEO
Mark T. Iwicki
IPO Date
2020-12-23
Sector
Healthcare
Industry
Medical - Pharmaceuticals
Exchange
NASDAQ
Country
US
Open
$2.15
Prev. Close
$2.11
Day Low
$2.11
Day High
$2.26
52W Low
$1.33
52W High
$2.36
Market Cap
$0.29B
Volume
1.07M
| 155,000 |
| $1.91 |
| 30 Jun 2026 | Canner David | director | A-Award | Acquired | 155,000 | $1.91 |
| 30 Jun 2026 | Kush Arvind | director | A-Award | Acquired | 155,000 | $1.91 |
| 30 Jun 2026 | Bellini Roberto | director | A-Award | Acquired | 155,000 | $1.91 |
| 30 Jun 2026 | Aurentz Vincent | director | A-Award | Acquired | 155,000 | $1.91 |
| 30 Jun 2026 | Munshi Amit | director | A-Award | Acquired | 155,000 | $1.91 |
| 24 Feb 2026 | Aurentz Vincent | director | D-Return | Disposed | 255,299 | $0.00 |
| 24 Feb 2026 | Cabell Christopher | President & Head of R&D | D-Return | Disposed | 338,282 | $0.00 |
| 24 Feb 2026 | Munshi Amit | director | D-Return | Disposed | 19,089 | $0.00 |